Sunshine Pharma Switches Compliance Adviser from China Sunrise Capital to Ignite Capital

Bulletin Express08-31

Sunshine Pharma (Sunshine Lake Pharma Co., Ltd.) has announced the termination of its compliance adviser agreement with China Sunrise Capital Limited, effective 31 August 2026. The decision, reached by mutual consent, follows the impending resignation of several responsible officers at China Sunrise Capital, which would leave the firm unable to meet the qualifications stipulated under Rule 3A.26 of Hong Kong’s Listing Rules.

Concurrently, the Board has appointed Ignite Capital (Asia Pacific) Limited as the new compliance adviser, also taking effect on 31 August 2026. Ignite Capital is licensed to conduct Type 1 (dealing in securities) and Type 6 (advising on corporate finance) activities under the Hong Kong Securities and Futures Ordinance.

Under the new agreement, Ignite Capital will advise Sunshine Pharma until the company fulfills Rule 13.46 requirements for publishing its first full-year financial results post-listing (covering the year ending 31 December 2026) or until the agreement is otherwise terminated, whichever occurs first.

Both Sunshine Pharma’s Board and China Sunrise Capital confirmed that no other matters related to the termination need to be brought to the attention of shareholders or the Stock Exchange.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144335596?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-31 18:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144335596","market":"us","top_or_hot":-1,"title":"Sunshine Pharma Switches Compliance Adviser from China Sunrise Capital to Ignite Capital","media":"Bulletin Express","content":"<p>Sunshine Pharma (Sunshine Lake Pharma Co., Ltd.) has announced the termination of its compliance adviser agreement with China Sunrise Capital Limited, effective 31 August 2026. The decision, reached by mutual consent, follows the impending resignation of several responsible officers at China Sunrise Capital, which would leave the firm unable to meet the qualifications stipulated under Rule 3A.26 of Hong Kong’s Listing Rules.</p>\n<p>Concurrently, the Board has appointed Ignite Capital (Asia Pacific) Limited as the new compliance adviser, also taking effect on 31 August 2026. Ignite Capital is licensed to conduct Type 1 (dealing in securities) and Type 6 (advising on corporate finance) activities under the Hong Kong Securities and Futures Ordinance.</p>\n<p>Under the new agreement, Ignite Capital will advise Sunshine Pharma until the company fulfills Rule 13.46 requirements for publishing its first full-year financial results post-listing (covering the year ending 31 December 2026) or until the agreement is otherwise terminated, whichever occurs first.</p>\n<p>Both Sunshine Pharma’s Board and China Sunrise Capital confirmed that no other matters related to the termination need to be brought to the attention of shareholders or the Stock Exchange.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sunshine Pharma Switches Compliance Adviser from China Sunrise Capital to Ignite Capital</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSunshine Pharma Switches Compliance Adviser from China Sunrise Capital to Ignite Capital\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-31 18:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sunshine Pharma (Sunshine Lake Pharma Co., Ltd.) has announced the termination of its compliance adviser agreement with China Sunrise Capital Limited, effective 31 August 2026. The decision, reached by mutual consent, follows the impending resignation of several responsible officers at China Sunrise Capital, which would leave the firm unable to meet the qualifications stipulated under Rule 3A.26 of Hong Kong’s Listing Rules.</p>\n<p>Concurrently, the Board has appointed Ignite Capital (Asia Pacific) Limited as the new compliance adviser, also taking effect on 31 August 2026. Ignite Capital is licensed to conduct Type 1 (dealing in securities) and Type 6 (advising on corporate finance) activities under the Hong Kong Securities and Futures Ordinance.</p>\n<p>Under the new agreement, Ignite Capital will advise Sunshine Pharma until the company fulfills Rule 13.46 requirements for publishing its first full-year financial results post-listing (covering the year ending 31 December 2026) or until the agreement is otherwise terminated, whichever occurs first.</p>\n<p>Both Sunshine Pharma’s Board and China Sunrise Capital confirmed that no other matters related to the termination need to be brought to the attention of shareholders or the Stock Exchange.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06887","symbol_name":"东阳光药","start_time":0,"source_url":"","article_id":"1144335596","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144335596","pubTimestamp":1788171869,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sunshine Pharma (Sunshine Lake Pharma Co., Ltd.) has announced the termination of its compliance adviser agreement with China Sunrise Capital Limited, effective 31 August 2026. The decision, reached...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06887":"东阳光药"},"translate_title":"阳光医药将合规顾问从中国日出资本调至点火资本","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06887":1},"content_text":"Sunshine Pharma (Sunshine Lake Pharma Co., Ltd.) has announced the termination of its compliance adviser agreement with China Sunrise Capital Limited, effective 31 August 2026. The decision, reached by mutual consent, follows the impending resignation of several responsible officers at China Sunrise Capital, which would leave the firm unable to meet the qualifications stipulated under Rule 3A.26 of Hong Kong’s Listing Rules.\nConcurrently, the Board has appointed Ignite Capital (Asia Pacific) Limited as the new compliance adviser, also taking effect on 31 August 2026. Ignite Capital is licensed to conduct Type 1 (dealing in securities) and Type 6 (advising on corporate finance) activities under the Hong Kong Securities and Futures Ordinance.\nUnder the new agreement, Ignite Capital will advise Sunshine Pharma until the company fulfills Rule 13.46 requirements for publishing its first full-year financial results post-listing (covering the year ending 31 December 2026) or until the agreement is otherwise terminated, whichever occurs first.\nBoth Sunshine Pharma’s Board and China Sunrise Capital confirmed that no other matters related to the termination need to be brought to the attention of shareholders or the Stock Exchange.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144335596","isCrawlerRequest":true}